{
    "clinical_study": {
        "@rank": "57122", 
        "arm_group": {
            "arm_group_label": "SABR Boost Therapy", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether SABR boost therapy is effective in women\n      with locally advanced cervical cancer without increased risk of acute gastrointestinal (GI)\n      or genitourinary (GU) toxicity."
        }, 
        "brief_title": "Stereotactic Body Radiation Therapy (SABR) for Definitive Treatment of Locally Advanced Cervical Cancer", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Locally Advanced Cervical Cancer", 
        "condition_browse": {
            "mesh_term": "Uterine Cervical Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Patients enrolled in this study will receive 45 Gray (Gy) in 25 fractions of intensity\n      modulated external beam radiation therapy + weekly cisplatinum . Following the completion of\n      Intensity Modulated Radiation Therapy (IMRT), patients will receive 28 Gy in 4 fractions\n      using stereotactic body radiation therapy techniques."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        1  Locally Advanced stage Cervical Cancer 2. Zubrod performance status 0-2 3. Negative\n        urine or serum pregnancy test for women of child-bearing potential 4. Agree to use\n        adequate contraception (hormonal or barrier method of birth control; abstinence) prior to\n        study entry and for the duration of study treatment 5.  Not a candidate for intracavitary\n        brachytherapy\n\n        Exclusion Criteria:\n\n          1. Pregnancy\n\n          2. Concurrent untreated cancer excluding  non-Melanoma skin cancer\n\n          3. Previous pelvic radiation\n\n          4. Active Inflammatory Bowel disease, Collagen vascular disease - systemic lupus\n             erythematosus (SLE), scleroderma\n\n          5. Age <18\n\n          6. Unable to consent for study\n\n          7. Severely immunocompromised patients ( such as  Transplant , on immunosuppressive\n             drugs)"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "21", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02045433", 
            "org_study_id": "STU 082013-064"
        }, 
        "intervention": {
            "arm_group_label": "SABR Boost Therapy", 
            "intervention_name": "SABR Boost Therapy", 
            "intervention_type": "Radiation"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 30, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75235"
                }, 
                "name": "University of Texas - Southwestern Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study for Stereotactic Body Radiation Therapy (SABR) for Definitive Treatment of Locally Advanced Cervical Cancer (LACC)", 
        "overall_contact": {
            "last_name": "Kevin Albuquerque, M.D.", 
            "phone": "214-645-8525"
        }, 
        "overall_contact_backup": {
            "last_name": "Jean Wu, MSN", 
            "phone": "214-645-8525"
        }, 
        "overall_official": {
            "affiliation": "University of Texas Southwestern Medical Center", 
            "last_name": "Kevin Albuquerque, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective is to improve primary tumor local control of eligible LACC  using SABR as the mechanism for delivering boost therapy to 85%  at 2 years post treatment", 
            "measure": "Primary tumor local control", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02045433"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To determine the  acute ( <90 days) and late(90-365 days) grade >3 GI and GU toxicity as assessed by CTCAEv4  from the commencement of SABR boost", 
                "measure": "toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "one year"
            }, 
            {
                "description": "To determine the patient reported quality of life (FACT-CX): 5 predetermined time points for first year", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }
        ], 
        "source": "University of Texas Southwestern Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Texas Southwestern Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}